Int J Radiat Oncol Biol Phys

• 

  Publication Venue For

  • Changes on mid-chemoradiotherapy FDG-PET/CT for cervical cancer are associated with prognosis. 2019
  • Endothelial Cell-Derived Extracellular Vesicles Mitigate Radiation-Induced Hematopoietic Injury..  104:291-301. 2019
  • A Call for Change in the ABR Initial Certification Examination in Radiation Oncology..  104:17-20. 2019
  • Advanced Treatment Technique for Locally Advanced Cervical Cancer: Time for a Standard of Care Shift?.  103:1098-1099. 2019
  • Clarifying the Relative Impacts of Vascular and Nerve Injury That Culminate in Erectile Dysfunction in a Pilot Study Using a Rat Model of Prostate Irradiation and a Thrombopoietin Mimetic..  103:1212-1220. 2019
  • Delivered Dose Distribution Visualized Directly With Onboard kV-CBCT: Proof of Principle..  103:1271-1279. 2019
  • A Nomogram for Testosterone Recovery After Combined Androgen Deprivation and Radiation Therapy for Prostate Cancer..  103:834-842. 2019
  • Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma. 2019
  • Long-term Clinical Outcomes of Nonoperative Management With Chemoradiotherapy for Locally Advanced Rectal Cancer in the Veterans Health Administration..  103:565-573. 2019
  • First, Do No Harm..  103:295-296. 2019
  • Blocking Cyclin-Dependent Kinase 4/6 During Single Dose Versus Fractionated Radiation Therapy Leads to Opposite Effects on Acute Gastrointestinal Toxicity in Mice..  102:1569-1576. 2018
  • Association of Interim FDG-PET Imaging During Chemoradiation for Squamous Anal Canal Carcinoma With Recurrence..  102:1046-1051. 2018
  • Findings on Surveillance Imaging After Preoperative Partial Breast Irradiation for Early Stage Breast Cancer..  102:1374-1381. 2018
  • Intratreatment Response Assessment With 18F-FDG PET: Correlation of Semiquantitative PET Features With Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy..  102:1002-1007. 2018
  • Defining the Place of Adjuvant Chemotherapy and Radiation for High-Risk Endometrial Cancer From Recent Randomized Clinical Trials: Some Answers, More Questions..  102:473-477. 2018
  • Correlation of Regional Lung Ventilation and Gas Transfer to Red Blood Cells: Implications for Functional-Avoidance Radiation Therapy Planning..  101:1113-1122. 2018
  • Development and Preliminary Evaluation of a Murine Model of Chronic Radiation-Induced Proctitis..  101:1194-1201. 2018
  • Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases..  101:845-853. 2018
  • Proton Therapy for Brain Metastases: A Question of Value..  101:830-832. 2018
  • Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group..  101:794-808. 2018
  • Scholarly Publishing and the Metric System..  101:784-785. 2018
  • Current Opportunities and Future Vision of Precision Medicine in Radiation Oncology..  101:267-270. 2018
  • How Advances in Imaging Will Affect Precision Radiation Oncology..  101:292-298. 2018
  • In Reply to Pratx and Kapp..  101:495-496. 2018
  • Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens..  101:396-405. 2018
  • Regional Nodal Irradiation in the Modern Era of Breast Cancer Management..  101:241-243. 2018
  • Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance)..  101:177-185. 2018
  • Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer..  100:1034-1043. 2018
  • Improving Quality and Consistency in NRG Oncology Radiation Therapy Oncology Group 0631 for Spine Radiosurgery via Knowledge-Based Planning..  100:1067-1074. 2018
  • Enhancing Radiation Therapy Through Cherenkov Light-Activated Phototherapy..  100:794-801. 2018
  • Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group..  100:652-669. 2018
  • Cardiac Morbidity and Radiation Therapy for Breast Cancer..  100:283-286. 2018
  • Chemo-radiation, Then on to Surgery..  100:290. 2018
  • Consensus Contouring Guidelines for Postoperative Completely Resected Cavity Stereotactic Radiosurgery for Brain Metastases..  100:436-442. 2018
  • Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer..  100:383-390. 2018
  • Single- and Multi-Fraction Stereotactic Radiosurgery Dose Tolerances of the Optic Pathways. 2018
  • Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy..  100:23-37. 2018
  • Time-Driven Activity-Based Costing in Oncology: A Step in the Right Direction..  100:95-96. 2018
  • Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA)..  99:812-816. 2017
  • Metastasis-Directed Therapy: Right for Some, but Not All, and Not Here..  99:767. 2017
  • Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer: The Hunt for the Silver Bullet..  99:761-763. 2017
  • Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma..  98:1022-1027. 2017
  • The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases..  98:1069-1077. 2017
  • Geriatric Assessment as a Predictor of Tolerance, Quality of Life, and Outcomes in Older Patients With Head and Neck Cancers and Lung Cancers Receiving Radiation Therapy..  98:850-857. 2017
  • Treatment of Gliomas: A Changing Landscape..  98:255-258. 2017
  • A Formal Assessment of the Dosimetric Advantages of Intensity-Modulated Radiation Therapy in Locally Advanced Lung Cancer..  98:234. 2017
  • Effects of Motion on Radiomics Analysis of Thoracic Cancers..  98:250. 2017
  • Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer With COX- 2 Overexpression: CALGB 30801 (Alliance)..  98:220-221. 2017
  • Quantitative Approach to Failure Mode and Effect Analysis for Linear Accelerator Quality Assurance..  98:56-62. 2017
  • Three-Dimensional Dosimetric Validation of a Magnetic Resonance Guided Intensity Modulated Radiation Therapy System..  97:1095-1104. 2017
  • Six Questions to Ask Before We Shorten Radiation Treatments for Intact Prostate Cancer..  97:718-721. 2017
  • Benchmark Credentialing Results for NRG-BR001: The First National Cancer Institute-Sponsored Trial of Stereotactic Body Radiation Therapy for Multiple Metastases..  97:155-163. 2017
  • Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study..  96:1046-1053. 2016
  • Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy..  96:547-555. 2016
  • "Going for Broke": Out-of-Pocket Costs, Financial Distress, and Patient-Reported Willingness to Pay and Sacrifice in Cancer Care..  96:S135-S136. 2016
  • (18)F-FDG PET/CT Response at 20 Gy Predicts Treatment Outcome for Head and Neck Squamous Cell Carcinoma (HNSCC)..  96:E378. 2016
  • Acute Toxicity in Patients With HER2-Positive Breast Cancer Treated With Adjuvant Radiation Therapy and Concurrent Trastuzumab and Pertuzumab..  96:E9-E10. 2016
  • Anaplastic (Malignant) Meningioma: A Patterns-of-Care and Outcomes Analysis of the National Cancer Data Base..  96:E76. 2016
  • Anti-PD-1 Therapy and Stereotactic Radiation for Melanoma and Non-Small Cell Lung Cancer Patients with Brain Metastases: A 2-Institution Series..  96:E97-E98. 2016
  • Benefit of Elective Nodal Irradiation and Androgen Deprivation Therapy with Postprostatectomy Salvage Radiation Therapy for Prostate Cancer..  96:S102. 2016
  • Biological Predictors of Radiation Esophagitis in Locally Advanced Lung Cancer: A Secondary Analysis From a Prospective Study..  96:E442-E443. 2016
  • Chemoradiation Versus Chemotherapy or Radiation Alone in Stage III Endometrial Cancer: Patterns of Care and Impact on Overall Survival..  96:E286. 2016
  • Computed Tomography Consensus Clinical Target Volume Contouring for Intensity Modulated Radiation Therapy in Intact Cervical Carcinoma..  96:S13-S14. 2016
  • Development of a Machine Learning Methodology to Estimate Lung Stereotactic Body Radiation Therapy Dosimetric Endpoints Based on Patient-Specific Anatomic Features..  96:E420-E421. 2016
  • Development of an Ultra-Fast, High-Quality Whole-Breast Radiation Therapy Treatment Planning System..  96:S228. 2016
  • Dosimetric Effect of the Breast Board and Couch Top for Whole-Breast Radiation Therapy in the Prone Position..  96:E46-E47. 2016
  • Early-Stage Breast Radiation Therapy Assessment Using Transcytolemmal Water Exchange Analysis of DCE-Magnetic Resonance Imaging: Initial Results..  96:E617. 2016
  • Etiology of Radiation-Induced Erectile Dysfunction: Vessel or Nerve?.  96:E590-E591. 2016
  • Evaluation of Dose-Volume Metrics of an 18F-FDG Positron Emission Tomography Adaptive Treatment Planning Protocol for Gynecological Malignancies..  96:E296. 2016
  • FDG Positron Emission Tomography (PET)/Computed Tomography Characteristics of Vulvar Cancer: Posttreatment PET Correlates With Clinical Outcomes..  96:S52-S53. 2016
  • FDG Positron Emission Tomography as an Indicator of Myelosuppression in Women Undergoing Pelvic Chemoradiation Therapy..  96:E293. 2016
  • Feasibility of Delivered Radiation Dose Using Cone Beam Computed Tomography as a Secondary Endpoint in a Phase 1 Trial of MOSART Stereotactic Body Radiation Therapy and Pembrolizumab for Metastatic Solid Tumors..  96:E631-E632. 2016
  • Immune Checkpoint Inhibition and Radiation Therapy in 2 Primary Mouse Models of Soft Tissue Sarcoma: Impact of Tumor Mutational Load..  96:E578-E579. 2016
  • Interim Acute Toxicity Analysis and Surgical Outcomes of Neoadjuvant Gemcitabine/nab-Paclitaxel and Hypofractionated Image Guided Intensity Modulated Radiation Therapy in Resectable and Borderline Resectable Pancreatic Cancer (ANCHOR) Study..  96:S204-S205. 2016
  • Interim FDG Positron Emission Tomography Imaging During Chemoradiation for Squamous Anal Canal Carcinoma..  96:E183. 2016
  • Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With Radiation Therapy: A Single-Institution Retrospective Analysis..  96:E83-E84. 2016
  • NRG Oncology/RTOG 0415, Phase 3 Noninferiority Study Comparing 2 Fractionation Schedules in Patients With Low-Risk Prostate Cancer: Prostate-Specific Quality of Life Results..  96:S2-S3. 2016
  • Outcome Analysis of Treatment in Stage IIA, T3N0 Rectal Adenocarcinoma in the Veterans Health Administration (VHA)..  96:E186. 2016
  • Oxygen and Perfusion Kinetics in Response to Fractionated Radiation Therapy in FaDu Head and Neck Cancer Xenografts Are Related to Treatment Outcome..  96:462-469. 2016
  • Patterns of Care and Outcomes Analysis for Gliosarcoma: A National Cancer Data Base Project..  96:E96. 2016
  • Prostate Cancer-Specific Mortality and Survival Outcomes for Salvage Radiation Therapy After Radical Prostatectomy..  96:S101. 2016
  • Radiation Oncologists' Practice Patterns and Attitudes Regarding Neoadjuvant Short-Course Radiation Therapy for Rectal Cancer in the United States..  96:S203. 2016
  • Simultaneous Integrated Boost (SIB) for Treatment of Gynecological Malignancies: Intensity Modulated Radiation Therapy (IMRT) Versus Volumetric Modulated Arc Therapy (VMAT)..  96:E677-E678. 2016
  • Survival With Stereotactic Body Radiation Therapy (SBRT) and Conventional Radiation Therapy (CRT) in Stage I Non-Small Cell Lung Cancer Patients in the Veterans Affairs System..  96:S9. 2016
  • The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases..  96:406-413. 2016
  • The Effect of Gene Mutations on Survival in Patients With Melanoma Following the Development of Brain Metastases..  96:S178. 2016
  • The Impact of Time to Treatment Initiation for Adjuvant Chemotherapy and Radiation Therapy in Stage III Endometrial Cancer: A National Cancer Data Base Study..  96:E287. 2016
  • The Use of Reirradiation in Locally Recurrent, Nonmetastatic Rectal Cancer..  96:E192-E193. 2016
  • Total Treatment Duration for Cervical Cancer: Is 55 Days Still the Goal in the Era of Concurrent Chemotherapy?.  96:S15. 2016
  • Toxicity and Quality of Life Report of a Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) for Low- and Intermediate-Risk Prostate Cancer..  96:E256-E257. 2016
  • Toxicity and Survival for Metastatic Melanoma Patients Treated With Anti-PD1 Therapy and Radiation Treatment..  96:S158-S159. 2016
  • Ultrafast Volumetric Cine Magnetic Resonance Imaging (UVC-MRI) for Real-Time 3-Dimensional Target Localization/Tracking..  96:E626. 2016
  • Vaginal Toxicity From Vaginal Brachytherapy and Capri-Based Systems..  96:E287-E288. 2016
  • Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer..  96:21-29. 2016
  • Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab..  96:72-77. 2016
  • A Technique for Generating Volumetric Cine-Magnetic Resonance Imaging..  95:844-853. 2016
  • Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)..  95:632-646. 2016
  • Vaginal Dose Is Associated With Toxicity in Image Guided Tandem Ring or Ovoid-Based Brachytherapy..  94:1099-1105. 2016
  • In Reply to Fiorino and Cozzarini..  94:860-861. 2016
  • In regard to Wu and Vapiwala et al..  94:858-859. 2016
  • Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer..  94:605-611. 2016
  • RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704..  94:554-560. 2016
  • Variation in Definitive Therapy for Localized Non-Small Cell Lung Cancer Among National Comprehensive Cancer Network Institutions..  94:360-367. 2016
  • In the Modern Treatment Era, Is Breast Conservation Equivalent to Mastectomy in Women Younger Than 40 Years of Age? A Multi-Institution Study..  93:1096-1103. 2015
  • Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer..  93:997-1004. 2015
  • Novel Manganese-Porphyrin Superoxide Dismutase-Mimetic Widens the Therapeutic Margin in a Preclinical Head and Neck Cancer Model..  93:892-900. 2015
  • A Roadmap for a New Academic Pathway for Global Radiation Oncology..  93:493-496. 2015
  • Preoperative Single-Fraction Partial Breast Radiation Therapy: A Novel Phase 1, Dose-Escalation Protocol With Radiation Response Biomarkers..  92:846-855. 2015
  • Are We Ready for a Radiological Terrorist Attack Yet? Report From the Centers for Medical Countermeasures Against Radiation Network..  92:504-505. 2015
  • The Cervix Cancer Research Network: A Global Outreach Effort on Behalf of the Gynecologic Cancer InterGroup..  92:506-508. 2015
  • Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel..  92:602-612. 2015
  • Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma..  92:54-59. 2015
  • Assessing adverse events of postprostatectomy radiation therapy for prostate cancer: evaluation of outcomes in the Regione Emilia-Romagna, Italy..  91:752-759. 2015
  • Nodal stage of surgically resected non-small cell lung cancer and its effect on recurrence patterns and overall survival..  91:765-773. 2015
  • Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1α maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature..  91:621-630. 2015
  • A hypothesis: indirect cell death in the radiosurgery era..  91:11-13. 2015
  • Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial..  91:100-108. 2015
  • Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer..  91:116-123. 2015
  • Whole-breast radiation therapy: the long and short of it..  90:990-992. 2014
  • Is diaphragm motion a good surrogate for liver tumor motion?.  90:952-958. 2014
  • Addressing the growing cancer burden in the wake of the AIDS epidemic in Botswana: The BOTSOGO collaborative partnership..  89:468-475. 2014
  • Comprehensive population-averaged arterial input function for dynamic contrast-enhanced vmagnetic resonance imaging of head and neck cancer..  89:658-665. 2014
  • Radiation oncology in Africa: improving access to cancer care on the African continent..  89:458-461. 2014
  • Reporting of uncertainty at the 2013 annual meeting of the American Society for Radiation Oncology..  89:222-223. 2014
  • Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes..  89:127-136. 2014
  • Assessing interpersonal and communication skills in radiation oncology residents: a pilot standardized patient program..  88:1129-1135. 2014
  • Four-dimensional magnetic resonance imaging using axial body area as respiratory surrogate: initial patient results..  88:907-912. 2014
  • Assessing cardiac injury in mice with dual energy-microCT, 4D-microCT, and microSPECT imaging after partial heart irradiation..  88:686-693. 2014
  • Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer..  88:553-564. 2014
  • Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary..  88:11-17. 2014
  • Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics..  88:195-203. 2014
  • The anatomy of radiation oncology residency training..  88:3-4. 2014
  • We need better figures!.  88:236. 2014
  • Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial..  87:638-645. 2013
  • ABR examinations: the why, what, and how..  87:237-245. 2013
  • On the need for comprehensive validation of deformable image registration, investigated with a novel 3-dimensional deformable dosimeter..  87:414-421. 2013
  • A knowledge-based approach to improving and homogenizing intensity modulated radiation therapy planning quality among treatment centers: an example application to prostate cancer planning..  87:176-181. 2013
  • Adaptive stereotactic body radiation therapy planning for lung cancer..  87:209-215. 2013
  • In reply to Kumar et al..  87:5-6. 2013
  • Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer..  87:88-93. 2013
  • Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines..  86:822-828. 2013
  • Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial..  86:873-879. 2013
  • Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy..  86:848-853. 2013
  • In regard to Shah..  86:596. 2013
  • Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer..  86:523-528. 2013
  • Agreement among RTOG sarcoma radiation oncologists in contouring suspicious peritumoral edema for preoperative radiation therapy of soft tissue sarcoma of the extremity..  86:298-303. 2013
  • Imaging primary mouse sarcomas after radiation therapy using cathepsin-activatable fluorescent imaging agents..  86:136-142. 2013
  • Oncology scan-treatment, consequences, and genomics in gastrointestinal cancer..  86:1-3. 2013
  • RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal..  86:27-33. 2013
  • Dual-energy micro-computed tomography imaging of radiation-induced vascular changes in primary mouse sarcomas..  85:1353-1359. 2013
  • Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer..  85:1332-1339. 2013
  • In regard to Rasmussen et al..  85:1153. 2013
  • Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy..  85:1375-1382. 2013
  • ATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy..  85:1066-1073. 2013
  • Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation..  85:1141-1148. 2013
  • Validating a prognostic scoring system for postmastectomy locoregional recurrence in breast cancer..  85:953-958. 2013
  • Osteoradionecrosis and radiation dose to the mandible in patients with oropharyngeal cancer..  85:415-420. 2013
  • Quantification and minimization of uncertainties of internal target volume for stereotactic body radiation therapy of lung cancer..  85:438-443. 2013
  • Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications..  85:175-181. 2013
  • Implementation of remote 3-dimensional image guided radiation therapy quality assurance for radiation therapy oncology group clinical trials..  85:271-277. 2013
  • Incorporating single-nucleotide polymorphisms into the Lyman model to improve prediction of radiation pneumonitis..  85:251-257. 2013
  • In regard to Yamamoto et al..  84:875-876. 2012
  • Chloroquine improves survival and hematopoietic recovery after lethal low-dose-rate radiation..  84:800-806. 2012
  • Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial..  84:e291-e297. 2012
  • Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging..  84:762-767. 2012
  • Reproducibility of tumor motion probability distribution function in stereotactic body radiation therapy of lung cancer..  84:861-866. 2012
  • A quality assurance method that utilizes 3D dosimetry and facilitates clinical interpretation..  84:540-546. 2012
  • Evaluation of the accuracy of a 3D surface imaging system for patient setup in head and neck cancer radiotherapy..  84:547-552. 2012
  • HSPB1 gene polymorphisms predict risk of mortality for US patients after radio(chemo)therapy for non-small cell lung cancer..  84:e229-e235. 2012
  • In Reply to O'Sullivan et al..  84:307-308. 2012
  • Frameless angiogram-based stereotactic radiosurgery for treatment of arteriovenous malformations..  84:274-282. 2012
  • Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy..  83:1126-1131. 2012
  • Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy..  83:e337-e343. 2012
  • Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas..  83:e353-e362. 2012
  • Local failure in resected N1 lung cancer: implications for adjuvant therapy..  83:727-733. 2012
  • Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer..  83:494-503. 2012
  • Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy..  83:362-368. 2012
  • Global reluctance to practice evidence-based medicine continues in the treatment of uncomplicated painful bone metastases despite level 1 evidence and practice guidelines..  83:1-2. 2012
  • A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246..  82:1967-1972. 2012
  • Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007..  82:e781-e786. 2012
  • Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases..  82:2111-2117. 2012
  • Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate..  82:e795-e801. 2012
  • Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas..  82:2018-2024. 2012
  • The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer..  82:1872-1879. 2012
  • The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection..  82:e773-e779. 2012
  • Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases..  82:1730-1737. 2012
  • Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer..  82:1367-1375. 2012
  • Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters..  82:e345-e350. 2012
  • A polymorphism within the promoter of the TGFβ1 gene is associated with radiation sensitivity using an objective radiologic endpoint..  82:e247-e255. 2012
  • Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value..  82:548-553. 2012
  • Anatomic tumor location influences the success of contemporary limb-sparing surgery and radiation among adults with soft tissue sarcomas of the extremities..  82:933-939. 2012
  • Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas..  82:809-816. 2012
  • Lipiodol: a potential direct surrogate for cone-beam computed tomography image guidance in radiotherapy of liver tumor..  82:834-841. 2012
  • Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme..  82:58-66. 2012
  • FDG-PET assessment of the effect of head and neck radiotherapy on parotid gland glucose metabolism..  82:321-326. 2012
  • Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers..  82:200-203. 2012
  • Preoperative single fraction partial breast radiotherapy for early-stage breast cancer..  82:37-42. 2012
  • Stereotactic body radiotherapy reirradiation for recurrent epidural spinal metastases..  81:1500-1505. 2011
  • The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704..  81:1328-1335. 2011
  • Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older..  81:e735-e741. 2011
  • Variation in the gross tumor volume and clinical target volume for preoperative radiotherapy of primary large high-grade soft tissue sarcoma of the extremity among RTOG sarcoma radiation oncologists..  81:e775-e780. 2011
  • Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas..  81:1081-1090. 2011
  • Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105..  81:e269-e274. 2011
  • RTOG sarcoma radiation oncologists reach consensus on gross tumor volume and clinical target volume on computed tomographic images for preoperative radiotherapy of primary soft tissue sarcoma of extremity in Radiation Therapy Oncology Group studies..  81:e525-e528. 2011
  • Functional polymorphisms of base excision repair genes XRCC1 and APEX1 predict risk of radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy..  81:e67-e73. 2011
  • Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma..  81:654-659. 2011
  • Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors..  81:812-818. 2011
  • Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline..  81:59-68. 2011
  • Multi-system verification of registrations for image-guided radiotherapy in clinical trials..  81:305-312. 2011
  • ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer..  80:1292-1298. 2011
  • Dosimetric effect of intrafraction motion and residual setup error for hypofractionated prostate intensity-modulated radiotherapy with online cone beam computed tomography image guidance..  80:453-461. 2011
  • The Holman Research Pathway in radiation oncology..  80:321-323. 2011
  • Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins?.  80:25-30. 2011
  • Local therapy for rhabdomyosarcoma of the hands and feet: is amputation necessary? A report from the Children's Oncology Group..  80:206-212. 2011
  • Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline..  79:965-976. 2011
  • Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial..  79:1248-1255. 2011
  • Teaching the anatomy of oncology: evaluating the impact of a dedicated oncoanatomy course..  79:853-859. 2011
  • American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer..  79:335-341. 2011
  • Digital tomosynthesis for respiratory gated liver treatment: clinical feasibility for daily image guidance..  79:289-296. 2011
  • Novel luciferase-based reporter system to monitor activation of ErbB2/Her2/neu pathway noninvasively during radiotherapy..  79:233-238. 2011
  • Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis..  78:1413-1419. 2010
  • Prostate intrafraction motion assessed by simultaneous kV fluoroscopy at MV delivery II: adaptive strategies..  78:1323-1330. 2010
  • Prostate intrafraction motion assessed by simultaneous kilovoltage fluoroscopy at megavoltage delivery I: clinical observations and pattern analysis..  78:1563-1570. 2010
  • Proteomic analysis of radiation-induced changes in rat lung: Modulation by the superoxide dismutase mimetic MnTE-2-PyP(5+)..  78:547-554. 2010
  • Impact of volumetric modulated arc therapy technique on treatment with partial breast irradiation..  78:288-296. 2010
  • The beginning of a new journal..  78:1-2. 2010
  • Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older..  77:1171-1177. 2010
  • An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control..  77:843-850. 2010
  • Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients..  77:655-661. 2010
  • Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer..  77:139-146. 2010
  • Clinical utility of the modified segmental boost technique for treatment of the pelvis and inguinal nodes..  76:1026-1036. 2010
  • Imaging primary lung cancers in mice to study radiation biology..  76:973-977. 2010
  • Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial..  76:998-1004. 2010
  • Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy..  76:796-801. 2010
  • Imaging for assessment of radiation-induced normal tissue effects..  76:S140-S144. 2010
  • Radiation dose-volume effects in the brain..  76:S20-S27. 2010
  • Radiation dose-volume effects in the spinal cord..  76:S42-S49. 2010
  • Radiation dose-volume effects in the stomach and small bowel..  76:S101-S107. 2010
  • Radiation dose-volume effects of optic nerves and chiasm..  76:S28-S35. 2010
  • Radiation-associated kidney injury..  76:S108-S115. 2010
  • Radiation-associated liver injury..  76:S94-100. 2010
  • Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes..  76:935-942. 2010
  • Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer..  76:361-368. 2010
  • Radiation-induced reductions in regional lung perfusion: 0.1-12 year data from a prospective clinical study..  76:425-432. 2010
  • Regional lung density changes after radiation therapy for tumors in and around thorax..  76:116-122. 2010
  • Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer..  75:1462-1467. 2009
  • Volumetric arc intensity-modulated therapy for spine body radiotherapy: comparison with static intensity-modulated treatment..  75:1596-1604. 2009
  • Adaptive replanning strategies accounting for shrinkage in head and neck IMRT..  75:924-932. 2009
  • Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer..  75:725-733. 2009
  • Multimodality surgical and hyperbaric management of mandibular osteoradionecrosis..  75:717-724. 2009
  • Dynamic MRI of grid-tagged hyperpolarized helium-3 for the assessment of lung motion during breathing..  75:276-284. 2009
  • Inferences about prostate intrafraction motion from pre- and posttreatment volumetric imaging..  75:260-267. 2009
  • American Society of Radiation Oncology recommendations for documenting intensity-modulated radiation therapy treatments..  74:1311-1318. 2009
  • Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO)..  74:987-1001. 2009
  • Accelerated partial breast irradiation: caution and concern from an ASTRO task force..  74:981-984. 2009
  • Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma..  74:1207-1216. 2009
  • ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate..  74:667-672. 2009
  • Association between RT-induced changes in lung tissue density and global lung function..  74:781-789. 2009
  • Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas..  74:824-830. 2009
  • RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer..  74:383-387. 2009
  • Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer..  74:377-382. 2009
  • A rabbit irradiation platform for outcome assessment of lung stereotactic radiosurgery..  73:1588-1595. 2009
  • Elective nodal irradiation for locally advanced non-small-cell lung cancer: it's called cancer for a reason..  73:1291-1292. 2009
  • Stereotactic body radiotherapy for lesions of the spine and paraspinal regions..  73:1369-1375. 2009
  • Dose-dependent effects of radiation therapy on cerebral blood flow, metabolism, and neurocognitive dysfunction..  73:1082-1087. 2009
  • The ethics of hypofractionation for prostate cancer..  73:969-970. 2009
  • Comparing digital tomosynthesis to cone-beam CT for position verification in patients undergoing partial breast irradiation..  73:952-957. 2009
  • Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors..  73:659-664. 2009
  • The role of seminal vesicle motion in target margin assessment for online image-guided radiotherapy for prostate cancer..  73:935-943. 2009
  • Quantifying the dosimetric trade-offs when using intensity-modulated radiotherapy to treat concave targets containing normal tissues..  73:585-593. 2009
  • Refinement of treatment setup and target localization accuracy using three-dimensional cone-beam computed tomography for stereotactic body radiotherapy..  73:571-577. 2009
  • Combination short-course preoperative irradiation, surgical resection, and reduced-field high-dose postoperative irradiation in the treatment of tumors involving the bone..  73:259-266. 2009
  • Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma..  73:148-153. 2009
  • Reproducibility of interfraction lung motion probability distribution function using dynamic MRI: statistical analysis..  72:1228-1235. 2008
  • Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809..  72:814-819. 2008
  • A prognostic scoring system for locoregional control in nasopharyngeal carcinoma following conformal radiotherapy..  66:992-1003. 2006
  • Impact of patient-specific factors, irradiated left ventricular volume, and treatment set-up errors on the development of myocardial perfusion defects after radiation therapy for left-sided breast cancer..  66:1125-1134. 2006
  • Health Care Disparities in Cancer Patients Receiving Radiation: Changes in Insurance Status After Medicaid Expansion Under the Affordable Care Act. 2018
  • Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial. 2017
  • Utility of Deep Inspiration Breath Hold for Left-Sided Breast Radiation Therapy in Preventing Early Cardiac Perfusion Defects: A Prospective Study. 2017
  • Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies. 2016
  • Lymphocyte predominance Hodgkin’s disease: High cure rate and acceptable complication rate with conventional treatment